Pancreatic Cancer
Conditions
Brief summary
Pancreatic cancer is the 5th leading cause of cancer death and the worst prognostic cancer in the world. This is due to high recurrent rate after surgical resection and poor response to chemotherapy and radiotherapy. Recent studies revealed that peri-tumoral structure and patients' immune status including cytotoxic immunity played significant role in the bad behavior of pancreatic cancer. While past studies focused on oncogenes and tumor suppressor genes, recent studies focused on patients' own immunity. Patients' immunity modified by cancer cells is found to be correlated to cancer progression and metastasis. Natural killer cells, playing an important role in cytotoxic immune system, are revealed to be decreased in patients with lung cancer, ovarian cancer, prostate cancer, colorectal cancer, and breast cancer. And in melanoma mouse model, when NK cell was suppressed, cancer progression and metastasis were accelerated. This study sought to find the correlation of patients' cytotoxic immune status to cancer progression and status by measurement of NK cell activity in pancreatic cancer patients. This would be basic support to construct a prognostic model of pancreatic cancer for early metastasis and post operational recurrence.
Interventions
PROCEDUREBlood collection
1ml of blood specimen collection
Sponsors
Yonsei University
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
DIAGNOSTIC
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
19 Years to 84 Years
Healthy volunteers
Yes
Inclusion criteria
* age over 18 and under 85 * Control group : incidental found benign pancreatic cyst, non-neoplastic gall bladder polyp (ex, cholesterol polyp), healthy people having no evidence of malignancy in check up within 1 year * Patient group : histological diagnosed pancreatic cancer patients, clinically diagnosed pancreatic cancer patients by radiologic evaluation * Agreed to enroll the study and signed informed consent
Exclusion criteria
* Patients with other malignancies within 5 years * Patients treated with steroid due to any reason within 1 year * Not signed informed consent
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Difference of the cytotoxic immune status | 24-hour after blood collection | Difference of the cytotoxic immune status between patients group and control group by comparing quantitative measurements of NK cell activities by ELISA kit |
| Difference of the severity of the pancreatic cancer | 24-hour after blood collection | Difference of the cytotoxic immune status according to the stage of the pancreatic cancer by comparing quantitative measurements of NK cell activities by ELISA kit |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Correlation of the cytotoxic immune status | 24-hour after blood collection | Correlation of the cytotoxic immune status with tumor markers |
Countries
South Korea
Outcome results
None listed